Cargando…

D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer

BACKGROUND: The complete mesogastrium excision (CME) based on D2 radical gastrectomy is believed to significantly reduce the local-regional recurrence compared with D2 radical gastrectomy in advanced gastric cancer, and it is widely used in China. This study aimed to explore whether D2 + CME is supe...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xiangyu, Wang, Lu, Liu, Guangcong, Zhang, Jun, Wang, Yue, Yang, Dong, Zheng, Guoliang, Zhang, Tao, Zheng, Zhichao, Zhao, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337254/
https://www.ncbi.nlm.nih.gov/pubmed/35276704
http://dx.doi.org/10.1097/CM9.0000000000002023
_version_ 1784759712908050432
author Meng, Xiangyu
Wang, Lu
Liu, Guangcong
Zhang, Jun
Wang, Yue
Yang, Dong
Zheng, Guoliang
Zhang, Tao
Zheng, Zhichao
Zhao, Yan
author_facet Meng, Xiangyu
Wang, Lu
Liu, Guangcong
Zhang, Jun
Wang, Yue
Yang, Dong
Zheng, Guoliang
Zhang, Tao
Zheng, Zhichao
Zhao, Yan
author_sort Meng, Xiangyu
collection PubMed
description BACKGROUND: The complete mesogastrium excision (CME) based on D2 radical gastrectomy is believed to significantly reduce the local-regional recurrence compared with D2 radical gastrectomy in advanced gastric cancer, and it is widely used in China. This study aimed to explore whether D2 + CME is superior to D2 on surgical outcomes during gastrectomy from Chinese data. METHODS: Feasible studies comparing the D2 + CME (D2 + CME group) and D2 (D2 group) published up to March 2020 are searched from electronic databases. The data showing surgical and complication outcomes are extracted to be pooled and analyzed. RESULTS: Fourteen records including 1352 patients were included. The D2 + CME group had a shorter mean operative time (weighted mean difference [WMD] = —16.72 min, 95% confidence interval [CI]: −26.56 to −6.87 min, P < 0.001), lower mean blood loss (WMD = −39.08 mL, 95% CI: −49.94 to −28.21 mL, P < 0.001), higher mean number of retrieved lymph nodes (WMD = 2.13, 95% CI: 0.58–3.67, P = 0.007), shorter time to first flatus (WMD = −0.31 d, 95% CI: −0.53 to − 0.10 d, P = 0.005), and postoperative hospital days (WMD = −1.09, 95% CI: −1.92 to −0.25, P = 0.010) than the D2 group. Subgroup analysis suggested that the advantages from the D2 + CME group were obvious in traditional open radical gastrectomy, proximal gastrectomy, and distal gastrectomy compared with D2 group. The evaluations of post-operative complications showed that the patients who underwent D2 + CME had a lower incidence of post-operative complications than the patients who underwent D2 surgery alone (relative risk [RR] = 0.65, 95% CI: 0.45–0.87, P = 0.003). The D2 radical gastrectomy plus CME improved 3-year overall survival (OS) (RR = 1.16, 95% CI: 1.02–1.32, P = 0.020) and lowered the local recurrence rate (RR = 0.51, 95% CI: 0.28–0.94, P = 0.030). The patients undergoing laparoscopic surgery or total gastrectomy had more significant advantages compared between D2 + CME and D2 groups in 3-year OS. CONCLUSION: The data from China show that D2 radical gastrectomy plus CME are reliable procedures and safety compared to D2 radical gastrectomy with faster recovery, lower risk, and better prognosis.
format Online
Article
Text
id pubmed-9337254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93372542022-08-01 D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer Meng, Xiangyu Wang, Lu Liu, Guangcong Zhang, Jun Wang, Yue Yang, Dong Zheng, Guoliang Zhang, Tao Zheng, Zhichao Zhao, Yan Chin Med J (Engl) Meta Analysis BACKGROUND: The complete mesogastrium excision (CME) based on D2 radical gastrectomy is believed to significantly reduce the local-regional recurrence compared with D2 radical gastrectomy in advanced gastric cancer, and it is widely used in China. This study aimed to explore whether D2 + CME is superior to D2 on surgical outcomes during gastrectomy from Chinese data. METHODS: Feasible studies comparing the D2 + CME (D2 + CME group) and D2 (D2 group) published up to March 2020 are searched from electronic databases. The data showing surgical and complication outcomes are extracted to be pooled and analyzed. RESULTS: Fourteen records including 1352 patients were included. The D2 + CME group had a shorter mean operative time (weighted mean difference [WMD] = —16.72 min, 95% confidence interval [CI]: −26.56 to −6.87 min, P < 0.001), lower mean blood loss (WMD = −39.08 mL, 95% CI: −49.94 to −28.21 mL, P < 0.001), higher mean number of retrieved lymph nodes (WMD = 2.13, 95% CI: 0.58–3.67, P = 0.007), shorter time to first flatus (WMD = −0.31 d, 95% CI: −0.53 to − 0.10 d, P = 0.005), and postoperative hospital days (WMD = −1.09, 95% CI: −1.92 to −0.25, P = 0.010) than the D2 group. Subgroup analysis suggested that the advantages from the D2 + CME group were obvious in traditional open radical gastrectomy, proximal gastrectomy, and distal gastrectomy compared with D2 group. The evaluations of post-operative complications showed that the patients who underwent D2 + CME had a lower incidence of post-operative complications than the patients who underwent D2 surgery alone (relative risk [RR] = 0.65, 95% CI: 0.45–0.87, P = 0.003). The D2 radical gastrectomy plus CME improved 3-year overall survival (OS) (RR = 1.16, 95% CI: 1.02–1.32, P = 0.020) and lowered the local recurrence rate (RR = 0.51, 95% CI: 0.28–0.94, P = 0.030). The patients undergoing laparoscopic surgery or total gastrectomy had more significant advantages compared between D2 + CME and D2 groups in 3-year OS. CONCLUSION: The data from China show that D2 radical gastrectomy plus CME are reliable procedures and safety compared to D2 radical gastrectomy with faster recovery, lower risk, and better prognosis. Lippincott Williams & Wilkins 2022-05-20 2022-03-10 /pmc/articles/PMC9337254/ /pubmed/35276704 http://dx.doi.org/10.1097/CM9.0000000000002023 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Meta Analysis
Meng, Xiangyu
Wang, Lu
Liu, Guangcong
Zhang, Jun
Wang, Yue
Yang, Dong
Zheng, Guoliang
Zhang, Tao
Zheng, Zhichao
Zhao, Yan
D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer
title D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer
title_full D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer
title_fullStr D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer
title_full_unstemmed D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer
title_short D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer
title_sort d2 lymphadenectomy with complete mesogastrium excision vs. conventional d2 gastrectomy for advanced gastric cancer
topic Meta Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337254/
https://www.ncbi.nlm.nih.gov/pubmed/35276704
http://dx.doi.org/10.1097/CM9.0000000000002023
work_keys_str_mv AT mengxiangyu d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT wanglu d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT liuguangcong d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT zhangjun d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT wangyue d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT yangdong d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT zhengguoliang d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT zhangtao d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT zhengzhichao d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer
AT zhaoyan d2lymphadenectomywithcompletemesogastriumexcisionvsconventionald2gastrectomyforadvancedgastriccancer